BioCentury

8:00 AM GMT, Dec 6, 2010
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 12/03 cls
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Brean Murray Jonathan Aschoff Price target Buy 2% $76.85
Leerink Howard Liang Price target Market outperform
Aschoff raised his target to $83 from $75 after Alexion reported final Phase II data on Nov. 20 at the American Society of Nephrology meeting that showed Soliris eculizumab met the primary endpoint in patients with atypical hemolytic uremic syndrome (aHUS).

Read the full 951 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.